RecruitingNot Applicable

Implementation of Point-of-Care Pharmacogenomic Decision Support Accounting for Minority Disparities

United States1,000 participantsStarted 2017-11-09

Plain-language summary

(a) To explore the feasibility and utility of implementing broad preemptive pharmacogenomic result delivery in the inpatient setting across multiple institutions specifically with the goal of incorporating minority-specific pharmacogenomic information; (b) To determine whether clinical outcomes for the drug warfarin are improved in African Americans through the availability of pharmacogenomics-based dosing guidance at the point-of-care.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients must be at least 18 years of age. * Patients must self-identify as African American Exclusion Criteria: * Patients who have undergone, or are being actively considered for, liver or kidney transplantation. * Patients with known active or prior leukemia. * Inability to understand and give informed consent to participate. * For patients being recruited to the warfarin sub-study, those with a glomerular filtration rate or creatinine clearance \<30 mL/min34.

What they're measuring

Frequency of Geonomic Prescribing System (GPS) use by physicians and pharmacists

Timeframe: Up to 5 years

Number of improved clinical outcomes

Timeframe: Up to 5 years

Trial details

NCT IDNCT03225820

SponsorUniversity of Chicago

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2028-03

Contact for this trial

Cancer Clinical Trials Office

1-855-702-8222 cancerclinicaltrials@bsd.uchicago.edu

View on ClinicalTrials.gov More Information Seeking Behavior trials